Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/187043
Title: | Use of glucocorticoids megadoses in SARS-CoV-2 infection in a spanish registry: SEMI-COVID-19 |
Author: | Lavilla Olleros, Cristina Ausín García, Cristina Bendala Estrada, Alejandro David Muñoz, Ana Wikman Jogersen, Philip Erick Fernández Cruz, Ana Giner Galvañ, Vicente Vargas, Juan Antonio Seguí Ripoll, José Miguel Rubio Rivas, Manuel Miranda Godoy, Rodrigo Mérida Rodrigo, Luis Fonseca Aizpuru, Eva Arnalich Fernández, Francisco Artero, Arturo Loureiro Amigo, Jose García García, Gema María Corral Gudino, Luis Jiménez Torres, Jose Casas Rojo, José Manuel Millán Núñez-Cortés, Jesús On Behalf of the SEMI-COVID-19 Network |
Keywords: | COVID-19 SARS-CoV-2 Epidemiologia Corticosteroides COVID-19 SARS-CoV-2 Epidemiology Adrenocortical hormones |
Issue Date: | 21-Jan-2022 |
Publisher: | Public Library of Science (PLoS) |
Abstract: | Objective To describe the impact of different doses of corticosteroids on the evolution of patients with COVID-19 pneumonia, based on the potential benefit of the non-genomic mechanism of these drugs at higher doses. Methods Observational study using data collected from the SEMI-COVID-19 Registry. We evaluated the epidemiological, radiological and analytical scenario between patients treated with megadoses therapy of corticosteroids vs low-dose of corticosteroids and the development of complications. The primary endpoint was all-cause in-hospital mortality according to use of corticosteroids megadoses. Results Of a total of 14,921 patients, corticosteroids were used in 5,262 (35.3%). Of them, 2,216 (46%) specifically received megadoses. Age was a factor that differed between those who received megadoses therapy versus those who did not in a significant manner (69 years [IQR 59-79] vs 73 years [IQR 61-83]; p < .001). Radiological and analytical findings showed a higher use of megadoses therapy among patients with an interstitial infiltrate and elevated inflammatory markers associated with COVID-19. In the univariate study it appears that steroid use is associated with increased mortality (OR 2.07 95% CI 1.91-2.24 p < .001) and megadose use with increased survival (OR 0.84 95% CI 0.75-0.96, p 0.011), but when adjusting for possible confounding factors, it is observed that the use of megadoses is also associated with higher mortality (OR 1.54, 95% CI 1.32-1.80; p < .001). There is no difference between megadoses and low-dose (p.298). Although, there are differences in the use of megadoses versus low-dose in terms of complications, mainly infectious, with fewer pneumonias and sepsis in the megadoses group (OR 0.82 95% CI 0.71-0.95; p < .001 and OR 0.80 95% CI 0.65-0.97; p < .001) respectively. Conclusion There is no difference in mortality with megadoses versus low-dose, but there is a lower incidence of infectious complications with glucocorticoid megadoses. |
Note: | Reproducció del document publicat a: https://doi.org/10.1371/journal.pone.0261711 |
It is part of: | PLOS ONE, 2022, vol. 17, num. 1, p. e0261711 |
URI: | http://hdl.handle.net/2445/187043 |
Related resource: | https://doi.org/10.1371/journal.pone.0261711 |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
journal.pone.0261711.pdf | 478.59 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License